Abstract
In the last few years the role and significance of the glia in CNS function and pathology have been drastically reassessed. Glial cells physiology appears very different in healthy versus pathological brain and the recent identification of cannabinoid receptors and their endogenous ligands in glia has triggered a number of studies exploring the role of (endo)cannabinoid system in glia functionality and disease. (Endo)cannabinoids exert their effects in these cells directly affecting some important peculiar functions of the glia and actively promoting biochemical signals ending in a prosurvival fate for these cells. By contrast, (endo)cannabinoids induce a selective death in glia-derived tumor cells. Of special physiological and therapeutic relevance is the reported ability of glial cells during neuropathological conditions to release an increased amount of endocannabinoids and to overexpress cannabinoid receptors. This evidence has suggested that the endocannabinoids production by glial cells may constitute an endogenous defense mechanism preventing the propagation of neuroinflammation and cell damage. The present paper will review the evidence supporting the regulatory role of (endo)cannabinoids in glia function, holding in consideration their therapeutic potential as neuroprotective and/or anticancer agents.
Keywords: Glia, microglia, astrocytes, oligodendrocytes, neuroprotection, cell survival, glioma
Current Pharmaceutical Design
Title: Expression and Function of the Endocannabinoid System in Glial Cells
Volume: 14 Issue: 23
Author(s): Paola Massi, Marta Valenti, Daniele Bolognini and Daniela Parolaro
Affiliation:
Keywords: Glia, microglia, astrocytes, oligodendrocytes, neuroprotection, cell survival, glioma
Abstract: In the last few years the role and significance of the glia in CNS function and pathology have been drastically reassessed. Glial cells physiology appears very different in healthy versus pathological brain and the recent identification of cannabinoid receptors and their endogenous ligands in glia has triggered a number of studies exploring the role of (endo)cannabinoid system in glia functionality and disease. (Endo)cannabinoids exert their effects in these cells directly affecting some important peculiar functions of the glia and actively promoting biochemical signals ending in a prosurvival fate for these cells. By contrast, (endo)cannabinoids induce a selective death in glia-derived tumor cells. Of special physiological and therapeutic relevance is the reported ability of glial cells during neuropathological conditions to release an increased amount of endocannabinoids and to overexpress cannabinoid receptors. This evidence has suggested that the endocannabinoids production by glial cells may constitute an endogenous defense mechanism preventing the propagation of neuroinflammation and cell damage. The present paper will review the evidence supporting the regulatory role of (endo)cannabinoids in glia function, holding in consideration their therapeutic potential as neuroprotective and/or anticancer agents.
Export Options
About this article
Cite this article as:
Massi Paola, Valenti Marta, Bolognini Daniele and Parolaro Daniela, Expression and Function of the Endocannabinoid System in Glial Cells, Current Pharmaceutical Design 2008; 14 (23) . https://dx.doi.org/10.2174/138161208785740135
DOI https://dx.doi.org/10.2174/138161208785740135 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Endothelin Receptors, Mitochondria and Neurogenesis in Cerebral Ischemia
Current Neuropharmacology Innovative Cancer Treatments that Augment Radiotherapy or Chemotherapy by the Use of Immunotherapy or Gene Therapy
Recent Patents on Anti-Cancer Drug Discovery Sigma Receptors and Cocaine Abuse
Current Topics in Medicinal Chemistry Targeting Cancer with Epi-Drugs: A Precision Medicine Perspective
Current Pharmaceutical Biotechnology At the Crossroads of TNF α Signaling and Cancer
Current Molecular Pharmacology Molecular Imaging of Cancer with Radiolabeled Peptides and PET
Anti-Cancer Agents in Medicinal Chemistry Clinical Evidence of Herb-Drug Interactions: A Systematic Review by the Natural Standard Research Collaboration
Current Drug Metabolism Calpain-Associated Proteolytic Regulation of the Stromal Microenvironment in Cancer
Current Pharmaceutical Design Base Excision Repair: Contribution to Tumorigenesis and Target in Anticancer Treatment Paradigms
Current Medicinal Chemistry Therapeutic Potential of Herbal Molecules against Breast Cancer
Current Nutrition & Food Science Flavonoids in Cancer Prevention
Anti-Cancer Agents in Medicinal Chemistry Regulation of Hypoxia-inducible Factor-1α and Vascular Endothelial Growth Factor Signaling by Plant Flavonoids
Mini-Reviews in Medicinal Chemistry The Neurotrophic and Antiangiogenic Functions of PEDF: A Reflection of its Variable Phosphorylation States
Current Genomics Induction of Antitumor Immune Responses with Recombinant Lentivector: Role of Skin Derived DCs
Current Cancer Therapy Reviews Inhibition of Angiogenesis as a Treatment Strategy for Neuroblastoma
Current Cancer Therapy Reviews The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy
Current Cancer Drug Targets Anticancer Mammalian Target of Rapamycin (mTOR) Signaling Pathway Inhibitors: Current Status, Challenges and Future Prospects in Management of Epilepsy
CNS & Neurological Disorders - Drug Targets Potential Cardio-Protective Agents: A Resveratrol Review (2000-2019)
Current Pharmaceutical Design The Bax Inhibitor-1 (BI-1) Family in Apoptosis and Tumorigenesis
Current Molecular Medicine Polyethylenimine as a Promising Vector for Targeted siRNA Delivery
Current Clinical Pharmacology